More than 50 million Americans, and almost 70% of all U.S. counties, have no radiation oncology providers and millions more ...

Cancer patients and their care teams are taking center stage in Amgen's newest online campaign. The Neulasta Onpro effort, dubbed Neulasta Onpro Narratives, highlights patients’ and professionals’ ...

Intas Pharma’s US specialty division, Accord BioPharma receives US FDA approval for Ennumo, a biosimilar to Neulasta: Raleigh, North Carolina Saturday, July 11, 2026, 12:00 Hrs ...

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and central nervous system (CNS) therapies, announced today that the U ...

The FDA approval of Fylnetra, a biosimilar for Neulasta, has the potential to offer patients with cancer a neutropenia treatment option at a lower cost. The Food and Drug Administration (FDA) approved ...

The FDA dealt Novartis’ Sandoz unit a blow last summer when it issued a complete response letter for the company’s biosimilar version of Amgen’s blockbuster drug Neulasta (pegfilgrastin). The Swiss ...

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta. The Food and Drug Administration (FDA) approved Udenyca Onbody, an injector ...

THOUSAND OAKS, Calif., (Sept. 15, 2005) – Amgen (Nasdaq: AMGN), the world's largest biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved an update to the ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other medications, ...

(Reuters) - Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA)30 declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Updated first-quarter Coherus BioSciences Inc. (NASDAQ: ...